Radiofrequency ablation (RFA) is a form of electrosurgery that can be minimally invasive and applied to many parts of the body. The EMcision RFA catheters are specific to endoscopically-applied, minimally invasive procedures: endoscopic ultrasound (EUS) and endoscopic retrograde cholangiopancreatography (ERCP). In these new explainer videos, you'll see the specifics of the devices in 3D modelling, and learn exactly how endoscopists use them.

Click here to see the videos.

Posted
AuthorKim Adams

As we continue to release the material from our insightful DDW focus group encounter, we shift the focus from the new Habib EUS RFA device to also look at the Habib EndoHPB device. Dr. William Brugge is a highly experienced physician in terms of RFA, and shared his findings of performing RFA inside metal stents.

See the video here.

Posted
AuthorKim Adams

During DDW 2016 we held a focus group where although the focus was the new Habib EUS RFA device, some of the biliary RFA experts such as Dr. William Brugge and Dr. Michel Kahaleh took the time to present their most recent thoughts and results with the Habib EndoHPB device. Dr. Michel Kahaleh discussed why he believes in adding RFA to the ERCP arsenal is important to consider.

Read more and see the presentation video.

Posted
AuthorKim Adams

Researchers sought to uncover whether patients with pancreatic cysts have a higher long-term risk of pancreatic cancer. Now published in GIE Journal, the paper points to statistically significant results that will hopefully lead to more similar studies and ultimately better inform the management of these patients. More here.

Posted
AuthorKim Adams

New data associates the application of RFA in the bile duct in conjunction with stenting to patient survival.  The study, published online by researchers from Cornell in the July issue of Digestive Diseases and Science, analyzed data collected prospectively on all patients admitted for biliary obstruction from pancreatic cancer or cholangiocarcinoma over a 3 year period.  Of the 66 patients included, 39% had RFA and stent whereas the remaining control group had stent only (the current standard of care).  Both groups were comparable for demographics, diagnosis and number of ERCPs performed.  No significant difference in the ratio of adverse events was observed.  A multivariable Cox proportional hazard statistical analysis determined the receipt of RFA to be one of the predictors of survival. 

To read the paper, click here.

Posted
AuthorFrancois Poulin

A national multicenter study from Austria (Dolak et al, 2013) published in the October issue of Surgical Endoscopy concluded that patients with malignant biliary obstructions benefited from extended survival when treated with the Habib EndoHPB.  The study, conducted in 11 centres, included 58 patients who underwent 84 procedures and presented levels of complications “not uncommon and [that] seem more to be caused by the poor general condition of the study population than by a certain medical intervention.”  Stent patency was 115 days for plastic stents and 218 days for metal stents, with a median survival after RFA of 10.6 months (this treatment modality was often used only when other treatment attempts had failed). Although the study was retrospective and involved a heterogeneous study population, the authors concluded that “the overall median survival of 17.9 months (from initial diagnosis until death) is much better than the survival rates documented for best supportive care, which barely exceed 12 months. It is even longer than most survival times reported for other palliative treatment modalities, such as PDT or stenting alone.”

To read the paper, click here!

Posted
AuthorCherif Habib

EMcision International Inc., a Montreal-based company specializing in advanced radiofrequency-based medical devices used in surgery, is pleased to announce it has sold its first units of the Habib™ RF DUO 13 catheter - a new device with immense potential to help abdominal cancer patients.

The Habib™ RF DUO 13 is a long, thin tube that sends electric pulses to destroy malignant cells. The device is currently approved for sale in Europe and China and the first batch was sold in recent days to medical professionals in those markets.

"The RF DUO 13 is groundbreaking and has real potential to improve the lives of those suffering from pancreatic cancer. We are honoured that top international surgeons have decided to begin a trial period with our minimally-invasive product," said Cherif Habib, CEO of EMcision.

The units sold to date will be used to treat more than 40 patients. Further shipments are planned in the coming weeks. The company hopes that the catheter will prolong the lives of cancer patients, but further clinical evidence is required.

"We look forward to working in close collaboration with our new partners to continue developing the RF DUO 13 and to expanding its reach," Mr. Habib concluded.

About EMcision

EMcision was founded by internationally renowned surgeon and inventor of medical devices, Professor Nagy Habib, to develop proprietary medical devices based on proven RF technology for the surgical community. Devices for endoscopists and interventional radiologists soon followed. In 2002, EMcision developed the Habib™ 4X for the treatment of liver cancer, which has the reputation of being the #1 hepatic resection device in the U.S. The company combines scientific, commercial and management skills, brought together in a working partnership to develop and commercialize medical devices that are clinically relevant, cost-effective and enhance the quality of life of cancer patients. EMcision's R&D, engineering and commercialization operations are based in Montreal, and clinical activities are based at the Imperial College London (U.K.) and Hammersmith Hospital.

 

Posted
AuthorCherif Habib